Neighborhood Environmental Attributes and Adults' Maintenance of Regular Walking
Takemi Sugiyama, Ai Shibata, Mohammad J Koohsari, Stephanie K Tanamas, Koichiro Oka, Jo Salmon, David W Dunstan, Neville Owen
Medicine & Science in Sports & Exercise | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
PURPOSE: Environmental initiatives to support walking are keys to noncommunicable disease prevention, but the relevant evidence comes mainly from cross-sectional studies. We examined neighborhood environmental attributes associated cross-sectionally with walking and those associated prospectively with walking maintenance. METHODS: Data were from the Australian Diabetes, Obesity and Lifestyle study collected in 2004-2005 (baseline) and in 2011-2012 (follow-up). Participants who did not move residence during the study period (n = 2684, age range: 30-77 yr at baseline) were categorized as regular walkers (walked five times per week or more) or not at baseline. Regular walkers were divided into ..View full abstract
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC
Awarded by Grants-in-Aid for Scientific Research
The AusDiab study was co-coordinated by the Baker IDI Heart and Diabetes Institute. We gratefully acknowledge the support and assistance given by: K. Anstey, B. Atkins, B. Balkau, E. Barr, A. Cameron, S. Chadban, M. de Courten, A. Kavanagh, D. Magliano, S. Murray, K. Polkinghorne, J. Shaw, T. Welborn, P. Zimmet, and all the study participants. For funding or logistical support, the authors thank the National Health and Medical Research Council (NHMRC; nos. 233200 and 1007544), Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd., Alphapharm Pty Ltd., Amgen Australia, AstraZeneca, Bristol-Myers Squibb, City Health Centre - Diabetes Service - Canberra, Department of Health and Community Services - Northern Territory, Department of Health and Human Services - Tasmania, Department of Health - New South Wales, Department of Health - Western Australia, Department of Health - South Australia, Department of Human Services - Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd., Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis, and sanofi-synthelabo. M. J. K. was supported by NHMRC Program Grant no. 569940. J. S. was supported by NHMRC Principal Research Fellowship no. 1026216. D.W.D. was supported by Australian Research Council Future Fellowship. N.O. was supported by NHMRC Program Grant no. 569940 and NHMRC Senior Principal Research Fellowship no. 1003960. Authors from Baker IDI Heart and Diabetes Institute were supported by the Victorian Government's Operational Infrastructure Support Program.